Stock listing
Milan:1BBIO BridgeBio Pharma, Inc. Azioni
Italian listing (Milan) of BridgeBio Pharma, Inc. · home listing NASDAQ:BBIO
Follow BridgeBio Pharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:BBIO
$76.03 USD -1.98 (-2.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BBIO
- Day range
- $75.46 – $78.22 USDNov 20, 2026
- Volume
- 1.48M sharesNov 20, 2026
- Market cap
- $14.86B USDAt the close on Nov 20, 2026 · price × 195.5M shares outstanding
- 52-week range
- $62.50 – $93.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $188.8M USDMedian day 2.48M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BBIO · Home | $76.03 USD | -1.98 (-2.5%) | 1,478,712 | $77.85 | $78.22 | $75.46 | $78.01 | Close on Nov 20, 2026 |
| Frankfurt:2CL | €70.31 EUR | -1.10 (-1.5%) | — | €69.98 | €70.31 | €69.98 | €71.41 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $76.03 | -1.98 | -2.5% | $77.85 | $78.22 | $75.46 | 1,478,712 | |
| $78.01 | +1.21 | +1.6% | $76.45 | $78.25 | $75.99 | 3,547,072 | |
| $76.80 | -0.56 | -0.7% | $76.74 | $77.10 | $74.75 | 2,812,198 | |
| $77.36 | -0.94 | -1.2% | $79.00 | $79.13 | $76.95 | 1,347,322 | |
| $78.30 | +0.13 | +0.2% | $78.60 | $79.13 | $77.58 | 1,149,255 | |
| $78.17 | -1.37 | -1.7% | $79.00 | $80.82 | $78.00 | 1,804,089 | |
| $79.54 | +0.87 | +1.1% | $78.86 | $79.74 | $77.80 | 2,324,843 | |
| $78.67 | +0.74 | +0.9% | $76.60 | $79.83 | $76.60 | 3,284,441 | |
| $77.93 | +3.64 | +4.9% | $74.58 | $78.06 | $73.49 | 3,000,166 | |
| $74.29 | +0.02 | 0.0% | $74.21 | $75.67 | $73.19 | 3,157,576 | |
| $74.27 | -3.62 | -4.6% | $77.90 | $78.58 | $74.11 | 3,383,543 | |
| $77.89 | +3.86 | +5.2% | $75.15 | $78.00 | $73.52 | 5,551,823 | |
| $74.03 | -0.965 | -1.3% | $75.48 | $76.79 | $73.95 | 2,478,768 | |
| $75.00 | +0.045 | +0.1% | $75.01 | $76.70 | $74.20 | 3,095,469 | |
| $74.95 | +4.22 | +6.0% | $72.85 | $75.65 | $71.91 | 5,770,977 | |
| $70.73 | -0.09 | -0.1% | $71.37 | $73.02 | $70.21 | 4,933,383 | |
| $70.82 | +1.45 | +2.1% | $68.79 | $71.18 | $68.65 | 3,111,389 | |
| $69.37 | +1.22 | +1.8% | $68.25 | $69.64 | $68.00 | 2,041,947 | |
| $68.15 | -0.41 | -0.6% | $68.56 | $68.82 | $67.89 | 2,059,129 | |
| $68.56 | +0.44 | +0.6% | $67.69 | $68.86 | $67.02 | 2,403,443 | |
| $68.12 | +0.38 | +0.6% | $67.48 | $69.32 | $67.07 | 2,780,421 | |
| $67.74 | +0.19 | +0.3% | $68.04 | $68.79 | $67.55 | 3,008,801 | |
| $67.55 | -0.39 | -0.6% | $68.28 | $69.00 | $67.25 | 2,732,829 | |
| $67.94 | +1.55 | +2.3% | $67.35 | $68.52 | $66.73 | 2,292,327 | |
| $66.39 | -0.74 | -1.1% | $67.03 | $67.04 | $65.26 | 2,055,500 | |
| $67.13 | +2.19 | +3.4% | $65.67 | $67.76 | $65.44 | 2,638,800 | |
| $64.94 | +1.64 | +2.6% | $63.34 | $65.36 | $62.86 | 2,700,500 | |
| $63.30 | -2.45 | -3.7% | $66.05 | $66.05 | $62.94 | 2,709,000 | |
| $65.75 | +0.40 | +0.6% | $65.35 | $66.42 | $65.20 | 1,778,900 | |
| $65.35 | +0.31 | +0.5% | $65.04 | $65.94 | $64.34 | 1,846,500 | |
| $65.04 | -1.46 | -2.2% | $66.39 | $66.41 | $63.70 | 3,362,000 | |
| $66.50 | -0.46 | -0.7% | $66.78 | $67.59 | $66.15 | 2,064,400 | |
| $66.96 | +0.82 | +1.2% | $67.75 | $68.12 | $65.71 | 3,709,900 | |
| $66.14 | -1.11 | -1.7% | $67.40 | $68.08 | $65.46 | 2,168,500 | |
| $67.25 | +0.34 | +0.5% | $67.10 | $68.68 | $66.23 | 2,646,100 | |
| $66.91 | +1.11 | +1.7% | $65.72 | $67.26 | $65.16 | 3,549,900 | |
| $65.80 | -0.17 | -0.3% | $66.14 | $67.32 | $65.61 | 2,822,400 | |
| $65.97 | -0.64 | -1.0% | $66.38 | $67.16 | $65.82 | 3,596,900 | |
| $66.61 | +1.04 | +1.6% | $65.07 | $67.34 | $64.36 | 2,969,300 | |
| $65.57 | -0.71 | -1.1% | $66.50 | $67.07 | $64.84 | 2,090,200 | |
| $66.28 | +0.57 | +0.9% | $65.85 | $67.30 | $65.33 | 4,271,600 | |
| $65.71 | -3.52 | -5.1% | $69.23 | $70.00 | $64.90 | 3,677,600 | |
| $69.23 | +2.65 | +4.0% | $66.90 | $69.77 | $66.61 | 3,782,400 | |
| $66.58 | -0.03 | 0.0% | $67.01 | $67.33 | $65.78 | 3,167,400 | |
| $66.61 | -0.70 | -1.0% | $67.39 | $67.56 | $66.10 | 4,103,500 | |
| $67.31 | -0.99 | -1.4% | $69.72 | $69.99 | $66.93 | 2,344,100 | |
| $68.30 | -0.09 | -0.1% | $68.52 | $69.46 | $67.11 | 4,785,800 | |
| $68.39 | -3.99 | -5.5% | $72.26 | $72.41 | $66.96 | 3,993,000 | |
| $72.38 | -0.06 | -0.1% | $72.55 | $73.67 | $72.17 | 1,851,300 | |
| $72.44 | -0.06 | -0.1% | $73.23 | $74.11 | $71.98 | 1,766,600 | |
| $72.50 | -3.58 | -4.7% | $75.27 | $75.50 | $72.12 | 3,064,100 | |
| $76.08 | +1.32 | +1.8% | $73.63 | $76.81 | $73.47 | 2,307,000 | |
| $74.76 | -0.08 | -0.1% | $73.60 | $76.34 | $73.26 | 2,094,500 | |
| $74.84 | -0.57 | -0.8% | $74.98 | $75.37 | $74.11 | 1,539,400 | |
| $75.41 | -1.09 | -1.4% | $76.43 | $76.64 | $75.20 | 1,098,000 | |
| $76.50 | -0.07 | -0.1% | $76.60 | $78.25 | $75.96 | 1,620,600 | |
| $76.57 | -0.02 | 0.0% | $76.61 | $77.45 | $76.22 | 1,448,500 | |
| $76.59 | -0.01 | 0.0% | $76.20 | $77.24 | $75.02 | 2,063,600 | |
| $76.60 | -2.08 | -2.6% | $79.99 | $80.55 | $76.34 | 1,922,100 | |
| $78.68 | -0.69 | -0.9% | $79.25 | $79.73 | $78.34 | 1,033,800 | |
| $79.37 | -1.03 | -1.3% | $79.75 | $80.76 | $79.33 | 1,705,000 | |
| $80.40 | -0.67 | -0.8% | $81.89 | $82.50 | $80.20 | 1,469,328 | |
| $81.07 | -0.43 | -0.5% | $80.98 | $81.68 | $80.16 | 1,113,409 | |
| $81.50 | -1.44 | -1.7% | $82.89 | $83.37 | $81.36 | 1,743,900 | |
| $82.94 | -1.01 | -1.2% | $83.51 | $84.37 | $82.63 | 2,030,600 |
- Ticker
- Milan:1BBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Milan
- Currency
- EUR
What changed lately
Latest news release · Nov 17, 2026
Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM
Latest earnings call · Oct 29, 2026
BridgeBio Pharma (NASDAQ:BBIO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · May 7, 2026
Q1 2026 Earnings Presentation
Earnings · 41 slides
Latest news
Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM
Nov 17, 2026
Closed $76.80 (-0.7%) on Nov 17, 2026
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
Nov 11, 2026
Closed $79.54 (+1.1%) on Nov 11, 2026
BridgeBio to Participate in November and December Investor Conferences
Nov 9, 2026
Closed $77.93 (+4.9%) on Nov 9, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2026
Closed $77.93 (+4.9%) on Nov 9, 2026
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
Nov 3, 2026
Closed $74.03 (-1.3%) on Nov 3, 2026
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
Oct 29, 2026
Closed $74.95 (+6.0%) on Oct 30, 2026
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4: 30 pm ET
Oct 22, 2026
Closed $68.12 (+0.6%) on Oct 22, 2026
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
Oct 6, 2026
Closed $66.50 (-0.7%) on Oct 7, 2026
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
Oct 6, 2026
Closed $66.50 (-0.7%) on Oct 7, 2026
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
Oct 6, 2026
Closed $66.96 (+1.2%) on Oct 6, 2026
BridgeBio Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 56 in the last 12 months · 275 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 7 calls with a replay · 7 with a transcript · latest Oct 29, 2026
- Decks
- 41 decks · latest May 7, 2026
Where BridgeBio Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BBIO · Home listing | NASDAQ | United States | USD |
| gettex:2CL | gettex | Germany | EUR |
| LS Exchange:A2PLX7 | LS Exchange | Germany | EUR |
| Tradegate:2CL | Tradegate | Germany | EUR |
| Lang & Schwarz:A2PLX7 | Lang & Schwarz | Germany | EUR |
| BX Swiss:BBIO | BX Swiss | Switzerland | CHF |
| Milan:1BBIO · This page | Milan | Italy | EUR |
| BOATS:BBIO | BOATS | United States | USD |
| Frankfurt:2CL | Frankfurt | Germany | EUR |
| Dusseldorf:2CL | Dusseldorf | Germany | EUR |
| Hamburg:2CL | Hamburg | Germany | EUR |
| Munich:2CL | Munich | Germany | EUR |
| Stuttgart:2CL | Stuttgart | Germany | EUR |
| BMV:BBIO | BMV | Mexico | MXN |
| Hanover:2CL | Hanover | Germany | EUR |
| Xetra:2CL | Xetra | Germany | EUR |
Valuation
EV/sales 16.9× against a median of 9.0×: 7th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $15.95B USD
- P/E
- Loss
- EV/sales
- 16.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- 94.3%
- Operating margin
- −38.5%
- Net margin
- −59.8%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. · NASDAQ:BBIO | US$14.86B | US$15.95B | n/a | 16.9× | n/a | n/a | −59.8% | n/a | 0.89 |
| Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY | US$19.26B | US$15.68B | 7.3× | n/a | n/a | 5.3× | n/a | 0.0× | 0.58 |
| Ascendis Pharma A/S · NASDAQ:ASND | US$16.73B | US$16.15B | 17.1× | 12.2× | 61.1× | 10.0× | 73.5% | 0.3× | 0.49 |
| Exelixis, Inc. · NASDAQ:EXEL | US$15.77B | US$14.88B | 17.8× | 6.0× | n/a | 8.6× | 35.4% | 0.0× | 0.69 |
| Neurocrine Biosciences, Inc. · NASDAQ:NBIX | US$15.24B | US$14.50B | 21.7× | 3.9× | n/a | 3.9× | 19.0% | 0.0× | 0.79 |
| PharmaEssentia Corp. · TWSE:6446 | US$15.10B | US$14.39B | 65.3× | 22.9× | 56.4× | 13.5× | 36.8% | 0.0× | n/a |
| BioMarin Pharmaceutical Inc. · NASDAQ:BMRN | US$11.70B | US$15.14B | n/a | 4.1× | 81.2× | 1.9× | −0.5% | 0.7× | 0.32 |
| Financiere de Tubize S.A. · EURONEXT:TUB | US$11.08B | US$11.02B | 108× | n/a | n/a | 5.1× | n/a | 0.0× | n/a |
| Halozyme Therapeutics, Inc. · NASDAQ:HALO | US$10.41B | US$12.59B | 21.5× | 7.0× | 18.2× | n/a | 26.9% | n/a | 0.63 |
| Kymera Therapeutics, Inc. · NASDAQ:KYMR | US$9.84B | US$8.87B | n/a | 86.8× | n/a | 6.1× | −341.8% | 0.0× | 0.92 |
| TG Therapeutics, Inc. · NASDAQ:TGTX | US$9.70B | US$9.94B | 91.4× | 11.1× | 51.5× | 16.9× | 11.8% | 1.3× | 0.70 |
| Median of the others | US$13.40B | US$14.45B | 21.6× | 9.0× | 56.4× | 6.1× | 22.9% | 0.0× | 0.66 |
Forecasts
14 strong buy · 5 buy · 3 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 106.85 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.49 · 7 analysts
- Revenue, year to Dec 2026
- 1.1B · 16 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Pedro J. Beltran | Chief Executive Officer, Idan Elmelech as Chief Operating Officer |
| Natalie Henchcliffe | COO |
| Daniel Nickle | Chief Legal Officer |
| Bubba Murarka | Executive Vice President |
| Chinmay Shukla | Senior Vice President |
| Mandy Rohrig | Vice President of Operations |
| Robert Cheng | Executive Vice President |
| Alex Fideler | Executive Director |
| Brian Koertgen | CTO |
| BridgeBio Pharma | Executive Chairman by the Board of Directors |
| Daniel Hong | |
| Hassan Jaroudi | Director of Finance |
| Kasia Gosek | Chief Strategy Officer |
| Lilian Zhang | Director of Research |
| Reed Ashford | |
| Scott Yahiro | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Alex Fideler | Executive Director |
| ContactKaitlyn Reilly | Director |
| ContactKristen Kelleher | Director |
| Daniel Hong | |
| Jeffrey Clarke | |
| Katherine Chang | |
| Reed Ashford |
Events
Calls
| Call | When | Status |
|---|---|---|
| BridgeBio Pharma (NASDAQ:BBIO) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 4:30 PM ET | Replay |
| BridgeBio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call | Mon, Aug 10, 2026 · 4:30 PM ET | Replay |
| BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| BridgeBio Pharma (NASDAQ:BBIO) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 4:30 PM ET | Replay |
| BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 4:30 PM ET | Replay |
| BridgeBio Pharma (NASDAQ:BBIO) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 4:30 PM ET | Replay |
| BridgeBio Pharma (NASDAQ:BBIO) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | +6.0% |
| Q2 2026 | Aug 10, 2026 · After close | −1.1% |
| Q1 2026 | May 7, 2026 · After close | −0.1% |
| Q4 2025 | Feb 19, 2026 | −7.8% |
| Q3 2025 | Oct 29, 2025 · After close | −4.9% |
| Q2 2025 | Aug 5, 2025 · After close | −8.9% |
| Q1 2025 | Apr 30, 2025 · Before open | +5.3% |
| Q4 2024 | Feb 20, 2025 · Before open | +1.4% |
| Q3 2024 | Nov 1, 2024 · Before open | +8.8% |
| Q2 2024 | Aug 1, 2024 · Before open | +0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +2.6% |
| Q4 2023 | Feb 22, 2024 · Before open | −1.6% |
| Q3 2023 | Nov 2, 2023 · Before open | +1.0% |
| Q2 2023 | Aug 3, 2023 · Before open | +0.3% |
| Q1 2023 | May 4, 2023 · Before open | −6.3% |
| Q4 2022 | Feb 23, 2023 · Before open | −4.6% |
| Q3 2022 | Nov 3, 2022 · Before open | −0.9% |
| Q2 2022 | Aug 4, 2022 · Before open | +25.7% |
| Q1 2022 | May 5, 2022 · Before open | −12.5% |
| Q4 2021 | Feb 24, 2022 · Before open | +9.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2026 Earnings Presentation | Earnings | 41 slides | May 7, 2026 |
| Investor Presentation (February 2026) | Investor deck | 92 slides | Feb 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 93 slides | Feb 24, 2026 |
| Technical Presentation (February 2026) | Technical | 32 slides | Feb 12, 2026 |
| Investor Presentation (January 2026) | Investor deck | 83 slides | Jan 12, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 48 slides | Jan 12, 2026 |
| Investor Day (January 2026) | Investor day | 36 slides | Jan 9, 2026 |
| Investor Presentation (October 2025) | Investor deck | 71 slides | Oct 29, 2025 |
| Technical Presentation (October 2025) | Technical | 29 slides | Oct 29, 2025 |
| Technical Presentation (October 2025) | Technical | 27 slides | Oct 27, 2025 |
All 41 decks
Financings
| Raise | Date |
|---|---|
| Preferred equity Closed: US$1B raised Buyers: Sixth Street (led the financing); HealthCare Royalty Use of proceeds: Fund three potential upcoming launches while continuing to invest in indication expansion across the pipeline | Aug 10, 2026 |
| Series A Cumulative Convertible Participating Preferred Stock Closed: convertible Buyers: Sixth Street (funded $800M as the lead investor); HealthCare Royalty (funded $133.9M) Use of proceeds: Strengthen the balance sheet and allocate capital across its highest return opportunities, including product launches | Jul 1, 2026 |
| 0.75% convertible senior notes due 2033 Update: US$550M Use of proceeds: Repurchase, settle conversions of or repay part of the 2.50% convertible notes due 2027, and general corporate purposes | Jan 15, 2026 |
| 1.75% convertible senior notes due 2031 Update: US$500M Use of proceeds: Repay and terminate the Blue Owl Financing Agreement, repurchase about $48.3 million of common stock, and general corporate purposes | Feb 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Jun 26, 2019.
- Price
- US$17.00 a share
- Shares offered
- 20,500,000 shares of common stock
- Offering size
- US$348.5 million
- Underwriters' option
- Up to 3,075,000 more shares
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets, Raymond James · In the order on the cover
- Shares delivered
- On or about Jul 1, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2019 |
| Filed publicly | May 24, 2019 |
| Amended 4 times | Newest Jun 26, 2019 |
| Shares registered with an exchange | Jun 26, 2019 |
| Declared effective by the SEC | Jun 26, 2019 |
| Final prospectus, with the price | Jun 28, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 28, 2019 |
| CERT · Exchange's certificate of listing | Jun 27, 2019 |
| EFFECT · Notice that a registration is effective | Jun 26, 2019 |
| S-1MEF · Registration of more shares for the same offering | Jun 26, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 26, 2019 |
| S-1/A · Registration statement, amended | Jun 26, 2019 |
| CORRESP · Letter to the SEC | Jun 25, 2019 |
| UPLOAD · Letter from the SEC | Jun 24, 2019 |
| CORRESP · Letter to the SEC | Jun 24, 2019 |
| CORRESP · Letter to the SEC | Jun 24, 2019 |
All 26 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jun 24, 2019 |
| S-1/A · Registration statement, amended | Jun 17, 2019 |
| CORRESP · Letter to the SEC | Jun 11, 2019 |
| CORRESP · Letter to the SEC | Jun 11, 2019 |
| S-1/A · Registration statement, amended | Jun 11, 2019 |
| UPLOAD · Letter from the SEC | May 30, 2019 |
| CORRESP · Letter to the SEC | May 24, 2019 |
| S-1 · Registration statement | May 24, 2019 |
| UPLOAD · Letter from the SEC | May 22, 2019 |
| DRSLTR · Letter to the SEC with a draft | May 16, 2019 |
| DRS/A · Draft registration statement, amended | May 16, 2019 |
| UPLOAD · Letter from the SEC | Apr 30, 2019 |
| DRSLTR · Letter to the SEC with a draft | Apr 16, 2019 |
| DRS/A · Draft registration statement, amended | Apr 16, 2019 |
| UPLOAD · Letter from the SEC | Mar 15, 2019 |
| DRS · Draft registration statement | Feb 14, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 502.1M | 221.9M | 9.30M | 77.6M | 69.7M | 8.25M | 40.6M | ||
| Cost of revenue | 21.0M | 3.88M | 2.45M | 3.43M | 3.11M | ||||
| Gross profit | 481.1M | 218.0M | 6.86M | 74.2M | 66.6M | ||||
| Research and development | 452.0M | 506.5M | 455.7M | 399.5M | 451.0M | 337.0M | 209.9M | 140.1M | 30.6M |
| Selling, general and administrative | 531.2M | 288.9M | 150.6M | 143.2M | 192.2M | 145.7M | 94.4M | ||
| Operating income | -523.4M | -593.0M | -607.4M | -512.2M | -576.6M | -474.5M | -266.2M | -183.7M | -43.9M |
| Depreciation and amortization | 5.43M | 6.08M | 6.49M | 6.77M | 5.84M | 1.46M | 859.0K | ||
| EBITDA | -518.0M | -586.9M | -600.9M | -505.4M | -570.8M | -473.0M | -265.4M | ||
| Interest expense | 53.1M | 91.0M | 81.3M | 80.4M | 46.8M | 36.7M | 8.77M | 2.55M | 13.0K |
| Income before tax | -732.5M | -542.2M | -653.3M | -484.7M | -586.5M | 505.5M | 288.6M | 169.5M | 43.8M |
| Income tax | 435.0K | 1.15M | 0 | 0 | |||||
| Net income | -724.9M | -535.8M | -643.2M | -481.2M | -562.5M | -448.7M | -260.6M | -130.7M | -30.6M |
| Earnings per share, basic | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | -2.12 | -1.00 |
| Earnings per share, diluted | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | -2.12 | -1.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 570.1M | 681.1M | 375.9M | 376.7M | 393.8M | 356.1M | 363.8M | 436.1M | 92.0M |
| Short-term investments | 17.4M | 0 | 0 | 51.6M | 393.7M | 251.0M | 182.2M | ||
| Receivables | 139.4M | 4.72M | 1.75M | ||||||
| Inventory | 26.8M | 0 | |||||||
| Current assets | 797.7M | 720.7M | 477.6M | 548.9M | 888.9M | 642.8M | 568.6M | 445.2M | |
| Property, plant and equipment | 5.37M | 7.01M | 11.8M | 14.6M | 30.1M | 20.3M | 5.63M | 1.57M | |
| Total assets | 936.0M | 919.3M | 546.4M | 623.0M | 1.01B | 703.6M | 631.7M | 464.9M | |
| Accounts payable | 36.2M | 9.62M | 10.7M | 11.6M | 11.9M | 8.95M | 8.85M | 13.5M | |
| Current liabilities | 288.0M | 154.4M | 143.8M | 121.4M | 135.1M | 95.6M | 60.4M | 32.6M | |
| Long-term debt | 437.3M | 446.4M | 431.0M | 430.8M | 92.4M | 91.8M | 54.5M | ||
| Total debt | 2.01B | 437.3M | 446.4M | 431.0M | 430.8M | 93.9M | 95.4M | 54.5M | |
| Total liabilities | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B | 595.7M | 155.7M | 87.6M | |
| Shareholders' equity | -2.09B | -1.47B | -1.35B | -1.25B | -870.4M | 57.9M | 408.5M | 314.9M | 85.9M |
| Shares outstanding | 194.8M | 190.0M | 175.1M | 150.6M | 147.3M | 122.8M | 123.7M | 92.1M | 123.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -445.9M | -520.7M | -527.7M | -419.5M | -497.9M | -399.7M | -253.6M | -136.6M | -40.5M |
| Capital spending | -1.10M | -933.0K | -1.31M | -4.82M | -13.2M | -7.52M | -2.64M | -2.18M | -464.0K |
| Free cash flow | -447.0M | -521.7M | -529.0M | -424.3M | -511.2M | -407.2M | -256.2M | -138.8M | -41.0M |
| Cash from investing | -24.5M | 60.8M | 54.0M | 453.1M | -200.8M | -53.0M | -217.3M | -21.0M | -464.0K |
| Cash from financing | 359.3M | 748.5M | 451.5M | -13.1M | 736.4M | 447.2M | 398.8M | 501.5M | 113.0M |
| Dividends paid | -997.0K | -1.15M | |||||||
| Share buybacks | -48.3M | 0 | 0 | 0 | -200.0M | -75.0M | |||
| Change in cash | -111.1M | 288.5M | -22.2M | 20.5M | 37.7M | -5.52M | -72.0M | 343.9M | 72.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 31, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 17, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 17, 2026 | Material contract | SEC |
| 424B7 · Prospectus | Aug 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Jul 24, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 24, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 10, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 2, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 8-K · Current report | May 8, 2026 | Material contract | SEC |
| S-3ASR · Registration statement | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 21, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Oct 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Aug 5, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Material contract | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 30, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
This page holds 200 of 840 filings. Open Filings
Cap table
Built by 6ix from BridgeBio Pharma, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 195,492,997
- Fully diluted
- 195,640,575
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 195,492,997 | |
| Options and RSUs | 147,578 | Nov 5, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 195,492,997 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Fred Hassan Other companies: Recursion Pharmaceuticals, Inc. (Director · Since Oct 31, 2026); EyePoint, Inc. (Director · Since at least Sep 3, 2024); Cocrystal Pharma, Inc. (Director · Since at least Apr 20, 2023); Precigen, Inc. (Director · Since at least Jun 30, 2016); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past) | Director · Since at least Aug 17, 2021 |
| Brent Saunders Other companies: Bausch + Lomb Corporation (Chairman of the Board and CEO, Director · Since at least Mar 6, 2023); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); SkinHealth Systems Inc. (Chairman · Since at least Sep 29, 2020); Cisco Systems, Inc. (Director · Mar 13, 2017 – Dec 8, 2022 · Past); Forest Laboratories Inc (CEO & President, Director · Aug 23, 2011 – Jun 30, 2014 · Past); Merck & Company, Inc. (Senior Vice President · May 19, 2006 – Nov 3, 2009 · Past) | Director · Jun 23, 2020 – Jun 22, 2022 · Past |
| Richard H. Scheller Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Alector, Inc. (Board Member · Since at least Feb 6, 2019); 23Andme Holding Co (Director · Jun 16, 2021 – Aug 26, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – May 20, 2021 · Past); Xenon Pharmaceuticals Inc. (Director · Mar 16, 2015 – Sep 16, 2019 · Past); Genentech Inc (EVP-RESEARCH · Jan 13, 2006 – Mar 26, 2009 · Past) | Director · Jun 27, 2019 – Feb 16, 2023 · Past |
| Charles Homcy Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Population Health Investment Co Inc (Director · Nov 17, 2020 – Jan 26, 2021 · Past); Pliant Therapeutics, Inc. (Director · Jun 2, 2020 – Jun 29, 2021 · Past); Portola Pharmaceuticals Inc (Director · Jun 8, 2018 – Jan 2, 2019 · Past); Global Blood Therapeutics Inc (Director · Oct 3, 2017 – Jun 20, 2018 · Past) | Director · Since at least Jun 27, 2019 |
| Ali J Satvat Other companies: Coherus Oncology, Inc. (Director · Since at least Nov 6, 2014); Impel Neuropharma Inc (Director · Apr 22, 2021 – Apr 22, 2021 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jan 26, 2021 · Past); PRA Health Sciences Inc (Director · Nov 12, 2014 – Nov 12, 2014 · Past) | Director · Since at least Jun 27, 2019 |
| Cameron Turtle Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Mar 23, 2026); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Spyre Therapeutics, Inc. (Chief Executive Officer · Since at least Jun 22, 2023); Eidos Therapeutics Inc (Chief Business Officer · Nov 5, 2018 – Jan 26, 2021 · Past) | See Remarks · Jun 27, 2019 – Dec 28, 2020 · Past |
| Frank McCormick Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Olema Pharmaceuticals, Inc. (Director · Sep 18, 2020 – Nov 23, 2020 · Past); Aduro Biotech Inc (Director · Apr 14, 2015 – Jun 6, 2018 · Past); Exelixis, Inc. (Director · May 2, 2006 – Dec 6, 2013 · Past) | Director · Since at least Jun 27, 2019 |
| Douglas A Dachille Other companies: PNC Financial Services Group, Inc. (the) (Director · Since at least Feb 3, 2025); Equitable Holdings, Inc. (Director · Since at least Jan 15, 2025); American International Group, Inc. New (EVP and CIO · Sep 30, 2015 – Jun 29, 2021 · Past) | Director · Since at least Aug 17, 2021 |
| Michael Henderson Other companies: Apogee Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Board Member · Since at least Jun 22, 2023); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past) | Chief Business Officer · Jun 27, 2019 – Dec 15, 2020 · Past |
| Andrew Lo Other companies: AbCellera Biologics Inc. (Director · Since at least Dec 3, 2021); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Sep 15, 2022 · Past) | Director · Since at least Jun 23, 2020 |
All 43 people
| Person | Seat |
|---|---|
| Brian M Stolz Other companies: Activision Blizzard Inc (Chief People Officer · May 31, 2016 – May 30, 2019 · Past); Bausch Health Companies Inc. (EVP, Administration & CHCO · Jul 20, 2013 – Jun 22, 2015 · Past) | Chief Operating Officer · Oct 9, 2019 – Aug 16, 2020 · Past |
| BridgeBio Pharma Other companies: Maze Therapeutics, Inc. (Director · Since at least Mar 25, 2026); Sensei Biotherapeutics, Inc. (Chief Financial Officer · Jun 15, 2026 – Nov 5, 2026 · Past) | Executive Chairman by the Board of Directors · Since at least Apr 22, 2026 |
| Hannah Valantine Other companies: CareDx, Inc. (Director · Since at least Jul 1, 2021); Pacific Biosciences of California, Inc. (Director · Since at least Jun 16, 2021) | Director · Since at least Oct 23, 2021 |
| James Momtazee Other companies: Roivant Sciences Ltd. (Nominating and Governance Committee Member · Since at least Oct 1, 2021); PRA Health Sciences Inc (Director · Aug 13, 2019 – Jul 1, 2021 · Past) | Director · Since at least Jun 27, 2019 |
| Jennifer E. Cook Other companies: Denali Therapeutics Inc. (Director · Since at least May 31, 2024); Jazz Pharmaceuticals plc (Director · Since at least Dec 4, 2023) | Director · Since at least Jun 21, 2024 |
| Neil Kumar Other companies: Maze Therapeutics, Inc. (Director · Since at least Mar 27, 2026); BridgeBio Oncology Therapeutics, Inc. (Executive Chairman · Since at least Aug 11, 2025) | Chief Executive Officer, Director · Since at least Nov 16, 2023 |
| Brian Stephenson Other companies: Sensei Biotherapeutics, Inc. (Chief Financial Officer · Since at least Nov 5, 2026) | CFO and Treasurer · Nov 16, 2020 – Feb 25, 2025 · Past |
| Eric Aguiar Other companies: Biomea Fusion, Inc. (Director · Since at least Jun 12, 2024) | Director · Since at least Jun 21, 2024 |
| Pedro J. Beltran Other companies: BridgeBio Oncology Therapeutics, Inc. (Chief Executive Officer · Since at least Aug 11, 2025) | Chief Executive Officer, Idan Elmelech as Chief Operating Officer · Since at least Apr 22, 2026 |
| Randal W Scott Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026) | Director · Since at least Dec 1, 2023 |
| Alex Fideler | Executive Director · Since at least Nov 4, 2026 |
| Andrea Ellis | Director · Since at least Aug 17, 2021 |
| Brian Koertgen | CTO · Since at least Nov 4, 2026 |
| Bubba Murarka | Executive Vice President · Since at least Mar 11, 2026 |
| Caleb Tripp | Chief Financial Officer · Feb 28, 2025 – Nov 4, 2026 · Past |
| Chinmay Shukla | Senior Vice President · Since at least Mar 30, 2026 |
| ContactKaitlyn Reilly | Director · Since at least Oct 5, 2026 |
| ContactKristen Kelleher | Director · Since at least Oct 5, 2026 |
| Daniel Hong | Director · Since at least Nov 5, 2026 |
| Daniel Nickle | Chief Legal Officer · Since at least Nov 4, 2026 |
| Hassan Jaroudi | Director of Finance · Since at least Nov 4, 2026 |
| Jeffrey Clarke | Director · Since at least Nov 5, 2026 |
| Kasia Gosek | Chief Strategy Officer · Since at least Nov 4, 2026 |
| Katherine Chang | Director · Since at least Nov 5, 2026 |
| Lilian Zhang | Director of Research · Since at least Nov 4, 2026 |
| Mandy Rohrig | Vice President of Operations · Since at least Nov 4, 2026 |
| Maricel Apuli | Chief Accounting Officer · Since at least Feb 19, 2025 |
| Natalie Henchcliffe | COO · Since at least Nov 4, 2026 |
| Reed Ashford | Director · Since at least Nov 5, 2026 |
| Robert Cheng | Executive Vice President · Since at least Nov 4, 2026 |
| Ronald J Daniels | Director · Since at least Jun 17, 2021 |
| Scott Yahiro | Chief Commercial Officer · Since at least Nov 4, 2026 |
| Thomas Trimarchi | President and CFO · Since at least Jul 23, 2024 |
Log in to ask 6ix AI your own questions about BridgeBio Pharma, Inc.